Free Trial

Alto Neuroscience (ANRO) Competitors

Alto Neuroscience logo
$3.08 0.00 (0.00%)
Closing price 07/25/2025 03:58 PM Eastern
Extended Trading
$3.05 -0.03 (-0.94%)
As of 07/25/2025 05:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANRO vs. SGMT, DBVT, ANNX, AVTE, ALLO, TVRD, ZYBT, CRDF, MREO, and KOD

Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Sagimet Biosciences (SGMT), DBV Technologies (DBVT), Annexon (ANNX), Aerovate Therapeutics (AVTE), Allogene Therapeutics (ALLO), Tvardi Therapeutics (TVRD), Zhengye Biotechnology (ZYBT), Cardiff Oncology (CRDF), Mereo BioPharma Group (MREO), and Kodiak Sciences (KOD). These companies are all part of the "pharmaceutical products" industry.

Alto Neuroscience vs. Its Competitors

Sagimet Biosciences (NASDAQ:SGMT) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Sagimet Biosciences has higher revenue and earnings than Alto Neuroscience. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sagimet Biosciences$2M157.03-$45.57M-$1.76-5.82
Alto NeuroscienceN/AN/A-$61.43M-$2.34-1.32

In the previous week, Alto Neuroscience had 8 more articles in the media than Sagimet Biosciences. MarketBeat recorded 22 mentions for Alto Neuroscience and 14 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.58 beat Alto Neuroscience's score of 0.22 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sagimet Biosciences
5 Very Positive mention(s)
4 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alto Neuroscience
1 Very Positive mention(s)
1 Positive mention(s)
20 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sagimet Biosciences has a beta of 3.35, suggesting that its stock price is 235% more volatile than the S&P 500. Comparatively, Alto Neuroscience has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Sagimet Biosciences currently has a consensus price target of $26.83, indicating a potential upside of 162.04%. Alto Neuroscience has a consensus price target of $8.50, indicating a potential upside of 175.97%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Sagimet Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagimet Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alto Neuroscience
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

87.9% of Sagimet Biosciences shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by company insiders. Comparatively, 11.1% of Alto Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Sagimet Biosciences' return on equity of -35.21% beat Alto Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Sagimet BiosciencesN/A -35.21% -34.09%
Alto Neuroscience N/A -39.35%-33.86%

Summary

Sagimet Biosciences beats Alto Neuroscience on 10 of the 14 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANRO vs. The Competition

MetricAlto NeuroscienceMED IndustryMedical SectorNYSE Exchange
Market Cap$83.38M$3.07B$5.70B$21.10B
Dividend YieldN/A2.37%4.58%3.59%
P/E Ratio-1.3221.1828.1028.44
Price / SalesN/A286.17429.0158.65
Price / CashN/A42.7636.2222.92
Price / Book0.558.378.664.69
Net Income-$61.43M-$55.19M$3.25B$995.51M
7 Day Performance10.79%5.88%4.22%1.65%
1 Month Performance33.62%17.33%10.51%4.54%
1 Year Performance-78.55%4.42%34.40%9.99%

Alto Neuroscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANRO
Alto Neuroscience
2.4184 of 5 stars
$3.08
flat
$8.50
+176.0%
-78.7%$83.38MN/A-1.32N/ATrending News
SGMT
Sagimet Biosciences
2.6844 of 5 stars
$9.46
-0.1%
$26.60
+181.2%
+201.2%$290.14M$2M-5.388News Coverage
Analyst Forecast
Insider Trade
DBVT
DBV Technologies
3.9053 of 5 stars
$10.58
-2.1%
$14.75
+39.5%
+85.8%$289.68M$4.15M-2.1580Upcoming Earnings
Gap Up
ANNX
Annexon
2.4473 of 5 stars
$2.61
+1.2%
$12.50
+378.9%
-59.4%$286.34MN/A-2.2160Gap Up
AVTE
Aerovate Therapeutics
N/A$9.82
-6.7%
N/A-87.6%$284.63MN/A-3.2820High Trading Volume
ALLO
Allogene Therapeutics
3.2638 of 5 stars
$1.29
+0.8%
$8.44
+554.6%
-48.5%$282.16M$20K-1.05310Analyst Revision
TVRD
Tvardi Therapeutics
N/A$29.83
+9.1%
$64.25
+115.4%
N/A$279.21M$7.14M0.0080Gap Up
High Trading Volume
ZYBT
Zhengye Biotechnology
N/A$5.87
-0.3%
N/AN/A$276.86M$186.36M0.00278
CRDF
Cardiff Oncology
1.3795 of 5 stars
$4.13
+1.5%
$11.70
+183.3%
+67.9%$274.77M$680K-4.4920Positive News
MREO
Mereo BioPharma Group
1.7911 of 5 stars
$1.72
+6.8%
$7.20
+318.6%
-56.9%$273.48M$10M-24.5740High Trading Volume
KOD
Kodiak Sciences
2.5297 of 5 stars
$5.17
+14.1%
$9.00
+74.1%
+174.5%$272.77MN/A-1.4290

Related Companies and Tools


This page (NYSE:ANRO) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners